ESR1 and breast carcinoma: Intriguingly, the collaboration between the signaling pathways of ER and other growth factor receptors (e.g., human epidermal growth factor receptor 2, HER2; epidermal growth factor receptor, EGFR; and insulin-like growth factor receptor, IGFR) have been reported to render the hormonal therapy resistant in breast cancer [6].